1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sage's Oral GABA-A Modulator Shows 'Dramatic' Effect On Depression

 
• By Mandy Jackson

CEO Jeff Jonas said the rapid and durable response to just two weeks of treatment with SAGE-217 coupled with the oral drug's safety in a short-term Phase II study support first-line use of the novel therapy, but plans for a Phase III depression program are not yet known.

MR image of Human brain

Sage Therapeutics Inc. CEO Jeff Jonas is so impressed with his company's oral depression drug candidate SAGE-217 based on Phase II results reported on Dec. 7 that even without Phase III data to back up the small mid-stage study he's willing to say that the efficacy seen to date supports first-line treatment.

Investors also were enthusiastic, sending the company's stock up 70% to close at $156.27 after Sage reported that patients who were treated with its oral GABA-A receptor modulator had a statistically significant mean reduction in Hamilton Rating Scale for Depression (HAM-D) scores of 17.6 points at day 15 versus a mean reduction of 10.7 points for patients who received a placebo (p<0.0001)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.